For people with overactive thyroid caused by Graves' disease or a toxic nodule, a single, carefully calculated dose of radioactive iodine can normalize thyroid function within six months without needing a second treatment.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether dosimetry-based RAI therapy consistently leads to higher rates of single-dose remission compared to fixed-dose RAI across diverse populations and settings.
A systematic review and meta-analysis of all published randomized controlled trials comparing dosimetry-based RAI (targeting 200–300 Gy) versus fixed-dose RAI (e.g., 555–740 MBq) in adults with Graves' disease or toxic adenoma, with primary outcomes of euthyroid/hypothyroid status at 6 and 12 months, retreatment rates, and radiation exposure. Studies must include at least 100 patients per arm and control for age, thyroid volume, and antithyroid drug use.
Whether dosimetry-based RAI causes a higher rate of single-dose remission than fixed-dose RAI in hyperthyroidism.
A double-blind, multicenter RCT of 200 adults (aged 18–75) with newly diagnosed Graves' disease or toxic adenoma, randomized to receive either dosimetry-based RAI (targeting 200 Gy for Graves', 300 Gy for adenoma) or fixed-dose RAI (555 MBq for Graves', 740 MBq for adenoma). Primary outcome: euthyroid or hypothyroid status at 6 months without retreatment. Secondary outcomes: radiation dose to non-target organs, time to euthyroidism, and recurrence at 12 months.
The long-term remission rate and hypothyroidism incidence following dosimetry-based RAI in real-world clinical practice.
A prospective cohort study of 500 patients with Graves' disease or toxic adenoma treated with dosimetry-based RAI (targeting 200–300 Gy) across multiple centers, followed for 5 years with annual thyroid function tests, ultrasound, and quality-of-life assessments. Must control for baseline thyroid volume, age, smoking, and antithyroid drug use.
Whether patients who fail to achieve remission after dosimetry-based RAI differ in baseline characteristics from those who succeed.
A case-control study comparing 50 patients who required retreatment after dosimetry-based RAI with 100 matched controls who achieved remission, analyzing pre-treatment factors: thyroid volume, iodine uptake, TSH receptor antibody levels, smoking status, and methimazole use duration.
The prevalence of euthyroidism or hypothyroidism in patients who received dosimetry-based RAI at a single point in time.
A cross-sectional survey of 300 patients who received dosimetry-based RAI at least 12 months prior, measuring current thyroid function, medication use, and patient-reported symptoms at one time point.